The 3D Bioprinting Patent Landscape Takes Shape as IP Leaders Emerge

3D bioprinting, a type of 3D printing, is a rapidly growing field with more players entering the arena every day. Complementing this growth, 3D bioprinting patent filings are trending upward. 3D bioprinting is a hot area for intellectual property (IP), given the innovation-rich and young technologies involved.

While 3D bioprinting uses some of the additive manufacturing principles of 3D printing, it also has many advancements of its own. For example, 3D bioprinting uses highly specialized biocompatible materials, sometimes called bio-inks,” that can include new polymers and even living cells. The machines used for 3D bioprinting are also highly specialized to handle the bio-inks safely, and to manufacture implants and tissue, and eventually, organs.

As one can imagine, a tremendous amount of research is needed to develop successful machines, methods, materials, processes, and products in this field. With so many aspects of 3D bioprinting being new and unprecedented, many companies and inventors are seeking patent protection to safeguard their efforts, while enriching the 3D bioprinting industry with their inventions. This article looks at how the 3D bioprinting field has grown, and at the emerging IP leaders.


Overview of the 3D Bioprinting Patent Landscape

To evaluate the 3D bioprinting patent landscape, we searched for worldwide patents and pending patent applications specifically directed toward 3D bioprinting. In April 2015, the search returned about 700 patents and pending applications, a sizeable number for an industry that is relatively new. In June 2016, the same search returned almost 950 patents and pending applications, a 36% increase in observable patent activity from 2015. We say “observable” because there could be many more unpublished patent applications that did not appear in the search results (more on this later).

3Dbioprinting 750


The Many Players, and the Few Leaders

The search identified over 100 companies that own 3D bioprinting patents or pending applications. The list was diverse, showing that innovations in the field are originating from many different parts of the world and from companies both big and small. Amidst the large pool of companies, there are trends and emerging leaders in 3D bioprinting patent protection. The chart below shows the companies with the largest portfolios of patents and published applications at this time (these companies may own patents or applications that were not picked up by the search, such as unpublished applications):

2015-2016 Top 3D Bioprinting Patent Assignees April 2015 October 2015 June 2016
Organovo Inc 32 32 66
Koninklijke Philips 30 37 33
Wake Forest University 29 29 40
Hewlett-Packard Company 29 39 29
The University Of Texas System 18 20 22
Medprin Regenerative Medical Technologies Co Ltd 14 14 14
Corning Incorporated 14 16 17


As a recognized leader and pioneer in 3D bioprinting, it was no surprise that Organovo made this list. Our time-lapsed search results showed that Organovo doubled its US and foreign IP portfolio in the past year alone. Wake Forest University and Koninklijke Philips, also at the top of this list, hold sizeable patent portfolios in 3D bioprinting, and the top 3 companies outnumber the rest by significant margins. Other companies and research universities are also steadily growing their patent portfolios, such as Hewlett-Packard, the University of Texas, Medprin Regenerative Medical Technologies, and Corning.

3D bioprinting inventions are originating from all corners of the world. The majority of the inventors of the 950 patents and applications resides in the United States, China, Japan, and South Korea. Companies own a majority of the patents and pending applications, but over 100 of the patents and applications are still owned by the original inventors. If/when ownership is transferred to a company, the IP portfolio leaderboard could change.


Issued Patents and Published Applications May Not Tell the Whole Story…

Our search included issued patents and “observable” patent applications, that is, applications that have been published, but there could be many unpublished applications that will eventually reveal a new 3D bioprinting IP powerhouse. Normally, patent applications are published 18 months after they are filed, and are secret until then. In the United States and some other countries, an applicant can request nonpublication of a patent application, in which case the public does not learn about the application until it becomes a patent.

Nonpublication is a tactic used to keep innovations secret while the application is pending, and this tactic can be especially useful when the patent application is pending for years. Issued patents are always published, so there are no secret patents in the 3D bioprinting industry. But just as 3D printing has stunned manufacturing industries, these currently unknown unpublished applications could yield new patent portfolios that shift power to industry newcomers. Time will tell, as the patent landscape evolves and both published and unpublished bioprinting patent applications issue as patents.

cellink and roosterbio 3D printing inks for bioprinting


The Patent Landscape is Ever-Changing

While this article identifies current IP leaders by portfolio size, the leaderboard will probably see some shuffling and new names in the coming years, as 3D bioprinted products inch closer to FDA approval and widespread use in clinics and hospitals. For example, companies are now partnering to develop and patent specific products, such as kidney cells, which may begin FDA testing in the coming years. For products that will interact or reside within the human body, FDA testing and approval is the gateway for many companies to profit. A path toward FDA approval will attract more companies and partnerships between companies, both of which usually bring more IP to the field. Companies with deeper pockets will purchase patents and acquire companies, thereby consolidating or shifting the bioprinting IP power structure. But portfolio size is not all that matters. A company with only a few patents could hold the secret sauce to a highly successful and FDA-approved product, so it is important not to count anyone out in this pioneering age for 3D bioprinting.